Source: econotimes

Press Release: Zosano Pharma : Zosano Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, today announced that it has approved inducement option grants to two new employees to purchase an aggregate of 100,000 shares of the Company’s common stock with an exercise price of $1.35 per share, which was the closing price on June 13, 2017.

Read full article »

Top Competitors or Alternatives

Looks like nobody has added any competitors for Zosano Pharma yet.

Missing a competitor? Contribute!

Annual Revenue
Steven Lo's photo - President & CEO of Zosano Pharma

President & CEO

Steven Lo

CEO Approval Rating


Zosano Pharma is a clinical-stage biopharmaceutical company that researches, develops and commercializes novel therapeutics to treat migraines. Read more